

Meeting of the Risk Communication Advisory Committee

March 6, 2018

FDA White Oak Campus, Building 31, the Great Room (Rm. 1503) 10903 New Hampshire Avenue, Silver Spring, MD 20993

AGENDA (DRAFT)

The Risk Communication Advisory Committee will discuss communicating risk information about fetal effects in product labeling according to the Pregnancy and Lactation Labeling Rule (PLLR), perception of risk and factors important to patients and prescribers, and societal factors that impact treatment decisions, to effectively assist patients and prescribers to make informed decisions about use of prescription drugs and vaccines in pregnancy.

9:00 a.m. Call to Order and Opening Susan J. Blalock, Ph.D., M.P.H.

Remarks Chair

Risk Communication Advisory Committee

Administrative Announcements **Lee Zwanziger, Ph.D.**

Designated Federal Officer

Risk Communication Advisory Committee

FDA

9:10 a.m. Open Public Hearing

9:30 a.m. Clarifying Questions

10:00 a.m. Committee Discussion

11:00 a.m. Break

11:15 a.m. Committee Discussion

12:30 p.m. Adjournment Susan J. Blalock, Ph.D., M.P.H.

Chair

Risk Communication Advisory Committee